Lilly’s U.S. Plant Flagged; European Cases Soar: Virus Update

U.S. drug-safety inspectors found continuing quality-control problems at a plant Eli Lilly & Co. is using to help produce its Covid-19 antibody therapy, posing a potential obstacle to the company meeting its goal of producing 1 million doses by year-end. Roche Holding AG warned that widespread shots this year are unlikely, adding to a chorus of caution on vaccines from industry leaders.